Table 2. Antiviral activity profile of various CBAs against the four serotypes of DENV.
| EC50 a | |||||
| CBA | Cell type | DENV-1 | DENV-2 | DENV-3 | DENV-4 |
| HHA (nM) | Raji/DC-SIGN | 54±13 | 34±13 | 29±3.6 | 92±32 |
| MDDC | 17±5.6 | 4.6±1.1 | 14±5.2 | 11±6 | |
| p-value | <0.05 | <0.05 | 0.05 | 0.099 | |
| GNA (nM) | Raji/DC-SIGN | 280±102 | 240±32 | 170±60 | 560±174 |
| MDDC | 22±4.2 | 3.8±1.5 | 11±4.4 | 5.6±1.4 | |
| p-value | 0.079 | <0.05 | 0.092 | <0.05 | |
| UDA (µM) | Raji/DC-SIGN | 2.4±0.87 | 1.4±0.34 | 3.2±1.3 | 7.0±2.0 |
| MDDC | 0.52±0.13 | 0.48±0.14 | 0.29±0.052 | 0.79±0.23 | |
| p-value | 0.12 | <0.05 | <0.001 | <0.05 | |
a
EC50: 50% effective concentration, or drug concentration required to inhibit DENV infection in Raji/DC-SIGN+ cells and MDDC by 50% as measured by viral antigen expression. Values are the mean ± SEM of 3 to 10 independent experiments. EC50 values for each lectin and each DENV serotype was compared between Raji/DC-SIGN+ cells and MDDC. p-values were calculated with a t-test.